Arena Pharma (ARNA) Strategic Update Adds Optionality to the Pipeline - Credit Suisse
Tweet Send to a Friend
Credit Suisse analyst Martin Auster reiterated an Outperform rating and $77.00 price target on Arena Pharma (NASDAQ: ARNA) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
